Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Micro-K for Liquid Suspension

Last reviewed on RxList: 12/26/2005
Drug Description

MICRO-KÒ LS
brand of Potassium Chloride Extended Release Formulation for Liquid Suspension

Rx Only

DESCRIPTION

Micro-K LS is an oral dosage form of microencapsulated potassium chloride. Each packet contains 1.5 g of potassium chloride, USP, equivalent to 20 mEqand of Potassium Chloride Extended Release Formulation for Liquid Suspension

of potassium. Micro-K LS is comprised of specially formulated granules. After reconstitution with 2-6 fluid ounces of water and 1 minute of stirring, the suspension is odorless and tasteless.

Each crystal of potassium chloride (KCl) is microencapsulated with an insoluble polymeric coating which functions as a semipermeable membrane; it allows for the controlled release of potassium and chloride ions over an 8- to 10-hour period. The controlled release of K+ ions by the microcapsular membrane is intended to reduce the likelihood of a high localized concentration of potassium chloride at any point on the mucosa of the gastrointestinal tract. Fluids pass through the membrane and gradually dissolve the potassium chloride within the microcapsules. The resulting potassium chloride solution slowly diffuses outward through the membrane.

Micro-K LS is an electrolyte replenisher. The chemical name of the active ingredient is potassium chloride and the structural formula is KCl. Potassium chloride, USP, occurs as a white, granular powder or as colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol.

Inactive ingredients: docusate sodium, ethylcellulose, povidone, silicon dioxide, sucrose, and another ingredient.

Indications

INDICATIONS

BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE IMMEDIATE-RELEASE LIQUIDS/EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS.

1. For the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia.

2. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal funsion, potassium losing nephropathy, and certain diarrheal states.

The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated.

SLIDESHOW

Health Screening Tests Every Woman Needs See Slideshow
Dosage

DOSAGE AND ADMINISTRATION

The usual dietary potassium intake by the average adult is 50 to 100 mEq per day. Potassium depletion sufficient to cause hypokalemia usually requires the loss of 200 or more mEq of potassium from the total body store.

Dosage must be adjusted to the individual needs of each patient. The dose for the prevention of the hypokalemia is typically in the range of 20 mEq per day. Doses of 40-100 mEq per day or more are used for the treatment of potassium depletion. Dosage should be divided if more than 20 mEq per day are given such that no more than 20 mEq is given in a single dose.

Usual Adult Dose: One Micro-K LS 20 mEq packet 1 to 5 times daily, depending on the requirements of the patient. This product must be suspended in a liquid, preferably water, or sprinkled on food prior to ingestion.

Suspension in Water: Pour contents of packet slowly into approximately 2-6 fluid ounces (1/4-3/4 glassful) of water. Stir thoroughly for approximately 1 minute until slightly thickened, then drink. The entire contents of the packet must be used immediately and not stored for future use. Any microcapsule/water mixture should be used immediately and not stored for future use.

Suspension in Liquids other than Water: Studies conducted using orange juice, tomato juice, apple juice and milk as the suspending liquid have shown that the quantity of fluid used to suspend one Micro-K LS packet MUST be limited to 2 fluid ounces (1/4 glassful). The use of volumes greater than 2 fluid ounces substantially reduces the dose of potassium chloride delivered. If a liquid other than water is used to suspend Micro-K LS, then the contents of the packet should be slowly poured into 2 fluid ounces (1/4 glassful) of liquid. Stir thoroughly for approximately 1 minute, then drink. The entire contents of the packet must be used immediately and not stored for future use. Any microcapsule/liquid mixture should be used immediately and not stored for future use.

Sprinkling Contents on Food: Micro-K LS may be given on soft food that may be swallowed easily without chewing, such as applesauce or pudding. After sprinkling the contents of the packet on the food, it should be swallowed immediately without chewing and followed with a glass of cool water, milk, or juice to ensure complete swallowing of all the microcapsules. Do not store microcapsule/food mixture for future use.

HOW SUPPLIED

Each packet of Micro-K LS brand potassium chloride extended-release formulation for liquid suspension contains 1.5 g microencapsulated potassium chloride (equivalent to 20 mEq K), and is packaged as follows:

Carton of 30 packets
Carton of 100 packets

Store at controlled room temperature 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room Temperature.]

CAUTION: Federal law prohibits dispensing without a prescription.
U.S. Patent No. 4,259,315
KV Pharmaceutical Co., St. Louis, MO 63044
Rev. 6/05
FDA rev date 8/05

Side Effects & Drug Interactions

SIDE EFFECTS

One of the most severe adverse effects is hyperkalemia (see CONTRAINDICATIONS, WARNINGS, and OVERDOSAGE).

Gastrointestinal bleeding and ulceration have been reported in patients treated with microencapsulated KCl (see WARNINGS).

In addition to bleeding and ulceration, perforation and obstruction have been reported in patients treated with solid KCl dosage forms, and may occur with Micro-K LS.

The most common adverse reactions to the oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. These symptoms are due to the irritation of the gastrointestinal tract and are best managed by taking the dose with meals, or reducing the amount taken at one time.

Skin rash has been reported rarely with potassium preparations.

In a controlled clinical study, Micro-K LS was associated with an increased frequency of gastrointestinal intolerance (e.g., diarrhea, loose stools, abdominal pain, etc.) compared to equal doses (100 mEq/day) of Micro-K Extencaps (see WARNINGS, Diarrhea or Dehydration). This finding was attributed to an inactive ingredient used in the Micro-K LS formulation that is not present in the Micro-K Extencaps formulation.

DRUG INTERACTIONS

Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: see WARNINGS.

Warnings

WARNINGS

Hyperkalemia (see OVERDOSAGE)

In patients with impaired mechanisms for excreting potassium, the administration of potassium salts can product hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment.

Interaction with Potassium-Sparing Diuretics

Hypokalemia should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene or amiloride) since the simultaneous administration of these agents can produce severe hyperkalemia.

Interaction with Angiotensin Converting Enzyme Inhibitors

Angiotensin converting enzyme (ACE) inhibitors (e.g., captopril, enalapril) will produce some potassium retention by inhibiting aldosterone production. Potassium supplements should be given to patients receiving ACE inhibitors only with close monitoring.

Gastrointestinal Lesions

Solid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract. Based on spontaneous adverse reaction reports, enteric-coated preparations of potassium chloride are associated with an increased frequency of small bowel lesions (40-50 per 100,000 patient years) compared to sustained-release was matrix formulations (less than 1 per 100,000 patient years). Because of the lack of extensive marketing experience with microencapsulated products, a comparison between such products and wax matrix or enteric-coated products is not available. Micro-K LS is administered as a liquid suspension of microencapsulated potassium chloride formulated to provide a controlled rate of release of potassium chloride and thus to minimize the possibility of a high local concentration of potassium near the gastrointestinal wall.

Prospective trials have been conducted in normal human volunteers in which the upper gastrointestinal tract was evaluated by endoscopic inspection before and after one week of solid oral potassium chloride therapy. The ability if this model to predict events occurring in usual clinical practice is unknown. Trials which approximated usual clinical practice did not reveal any clear differences between the wax matrix and microencapsulated dosage forms. In contrast, there was a higher incidence of gastric and duodenal lesions in subjects receiving a high dose of a wax matrix controlled-release formulation under conditions which did not resemble usual or recommended clinical practice (i.e., 96 mEq per day in divided doses of potassium chloride administered to fasted patients, in the presence of an anticholinergic drug to delay gastric emptying). The upper gastrointestinal lesions observed by endoscopy were asymptomatic and were not accompanied by evidence of bleeding (hemoccult testing). The relevance of these findings to the usual conditions (i.e., non-fasting, no anticholingeric agent, smaller doses) under which controlled-release potassium chloride products are used is uncertain; epidemiologic studies have not identified an elevated risk, compared to microencapsulated products, for upper gastrointestinal lesions in patients receiving wax matrix formulations. Micro-K LS should be discontinued immediately and the possibility of ulceration, obstruction or perforation considered if severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occurs.

Diarrhea or Dehydration

Micro-K LS contains, as a dispersing agent, docusate sodium, which also increases stool water and is used as a stool softener. Clinical studies with Micro-K LS indicate that minor changes in stool consistency may be common, although usually are well tolerated. However, rarely, patients may experience diarrhea or cramping abdominal pain. Patients with severe or chronic diarrhea or who are dehydrated ordinarily should not be prescribed Micro-K LS.

Metabolic Acidosis

Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.

Precautions

PRECAUTIONS

General

The diagnosis of potassium depletion is ordinarily made be demonstrating hypokalemia in a patient with a clinical history suggesting some cause for potassium depletion. In interpreting the serum potassium level, the physician should bear in mind that acute alkalosis per se can produce hypokalemia in the absence of a deficit in total body potassium while acute acidosis per se can increase the serum potassium concentration into the normal range even in the presence of a reduced total body potassium. The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis requires careful attention to acid-base balance and appropriate monitoring of serum electrolytes, the electrocardiogram, and the clinical status of the patient.

Laboratory Tests

Regular serum potassium determinations are recommended, especially in patients with renal insufficiency or diabetic nephropathy.

When blood is drawn for analysis or plasma potassium, it is important to recognize that artifactual elevations can occur after improper venipuncture technique or as a result of in vitro hemolysis of the sample.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity, mutagenicity, and fertility studies in animals have not been performed. Potassium is a normal dietary constituent.

Pregnancy

Nonteratogenic Effects Category C

Animal reproduction studies have not been conducted with Micro-K LS. It is unlikely that potassium supplementation that does not lead to hyperkalemia would have an adverse effect on the fetus or would affect reproductive capacity.

Nursing Mothers

The normal potassium ion content of human milk is about 13 mEq per liter. Since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk.

Pediatric Use

Safety and effectiveness in children have not been established.

Geriatric Use

Clinical studies of Micro-K LS did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patient are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Overdosage

OVERDOSE

The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, of if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result (see CONTRAINDICATIONS and WARNINGS). It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5-8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment, and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9-12 mEq/L).

Treatment measures for hyperkalemia include the following:

1. Elimination of foods and medications containing potassium and of any agents with potassium-sparing properties;

2. Intravenous administration of 300 to 500 mL/hr of 10% dextrose solution containing 10-20 units of crystalline insulin per 1,000 mL;

3. Correction of acidosis, if present, with intravenous sodium bicarbonate;

4. Use of exchange resins, hemodialysis, or peritoneal dialysis.

In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce digitalis toxicity.

The extended release feature means that absorption and toxic effects may be delayed for hours. Consider standard measures to remove any unabsorbed drug.

Contraindications

CONTRAINDICATIONS

Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency, or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene, amiloride) (see OVERDOSAGE).

Controlled-release formulations of potassium chloride have produced esophageal ulceration in certain cardiac patients with esophageal compression due to an enlarged left atrium. Potassium supplementation, when indicated in such patients, should be given as an immediate-release liquid preparation.

All solid oral dosage forms of potassium chloride are contraindicated in any patient in whom there is structural, pathological (e.g., diabetic gastroparesis) or pharmacologic (use of anticholinergic agents or other agents with anticholinergic properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in tablet or capsule passage through the gastrointestinal tract.

Clinical Pharmacology

CLINICAL PHARMACOLOGY

The potassium ion is in the principle intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle, and the maintenance of normal renal function.

The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane.

Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day.

Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a consequence of therapy with diuretics, primarily or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and, in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine.

If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.

In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients, potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.

Medication Guide

PATIENT INFORMATION

Physicians should consider reminding the patient of the following:

1. To take each dose with meals mixed in water or other suitable liquid.

2. To take this medicine following the frequency and amount prescribed by the physician. This is especially important if the patient is also taking diuretics and/or digitalis preparations.

3. To inform patients that this product contains as a dispersing agent the stool softener, docusate sodium, which may change stool consistency, or, rarely, produce diarrhea or cramps.

4. To check with the physician at once if tarry stools or other evidence of gastrointestinal bleeding is noticed.

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Health Solutions From Our Sponsors